BioCurity is a clinical stage biopharmaceutical company headquartered in Florida. BioCurity's technology, as tested at MD Anderson Cancer Center/Orlando Health, is expected to block adverse side effects experienced by patients undergoing radiation therapy, including skin damage, which may include dermatitis with inflammation, burning, necrosis, and scarring of normal skin. It is estimated that up to 90% of the 1 million cancer patients in the United States that receive essential radiation therapy during their cancer treatment have an adverse reaction and damage to normal tissue from the radiation exposure.1,2,3,4
BioCurity seeks to deliver a solution to a major problem of Breast Cancer patients undergoing radiation therapy with its first product. A topical dermatology product to prevent skin damage to women’s breast and surrounding tissue.
Key opinion leader physicians and advocates of cancer patient support programs understand the economic costs and severe toll this damage to healthy tissue inflicts on patients already struggling to fight their cancer. BioCurity is committed and making progress to reduce and prevent radiation side effects whose prevention remains an urgent, undeniable and material unmet clinical need for cancer patients.
1Siegel, Rebecca, et al. “Cancer Statistics, 2016.” CA Cancer J Clin. 66 (2016): 7-30
2Ryan, Julie. “Ionizing Radiation: The Good, the Bad, and the Ugly”. J Invest Dermatol. 132 (2012): 985-993
3Bray Fleta, et al. “Acute and Chronic Cutaneous Reactions to Ionizing Radiation Therapy.” Dermatol Ther. 6 (2016): 185-206
4Radvansky, Lauren, et al. “Prevention and management of radiation-induced dermatitis, mucositis and xerostomia.” Am J Health Syst Pharm. 12 (2013): 1025-1032